To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Inclusion criteria: * Diagnosis of rheumatoid arthritis (RA) ≥ 3 months. * Moderately to severely active rheumatoid arthritis. * Participants who per investigator judgment were incomplete responders to at least 12 weeks of an adequate dose of continuous treatment with or who were intolerant of one or a combination of non-biologic disease modifying anti-rheumatic drugs (DMARDs). Exclusion criteria: * Participants \< 18 years of age. * Past history of, or current, autoimmune or inflammatory systemic or localized joint disease(s) other than RA. * History of juvenile idiopathic arthritis or arthritis onset prior to age 16. * Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome. * Prior treatment with any biologic anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies. * Treatment with prednisone \> 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization. * New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors within 4 weeks prior to randomization, except for the use of low-dose acetylsalicylic acid for cardiovascular diseases. * Use of parenteral glucocorticoids or intra-articular glucocorticoids injection within 4 weeks prior to randomization. * Prior treatment with a Janus kinase (JAK) inhibitor (tofacitinib). * New treatment or dose-adjustment to on-going medication for dyslipidemia, such as statin, within 6 weeks prior to randomization. * Participation in any clinical research study evaluating another investigational drug or therapy within 5 half-lives or 60 days of first dose of study drug administration, whichever is longer. * Participants with a history of malignancy other than adequately-treated carcinoma in-situ of the cervix, non-metastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization visit. Non-malignant lymphoproliferative disorders are also excluded. * Participants with active tuberculosis or untreated latent tuberculosis infection. * Pregnant or breast feeding women. The above information is not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.